Business Context and Reporting Period
This Form 6-K filing by Kamada Ltd. (KAMADA), an Israeli biopharmaceutical company, was submitted on November 13, 2023. The document serves as a notice of the Annual General Meeting of Shareholders scheduled for December 28, 2023, and includes the accompanying Proxy Statement. The filing also discloses the immediate resignation of a long-serving director.
Key Financial Metrics
The filing does not contain current revenue, profit, cash flow, or debt metrics for the period ending November 2023. It references the audited consolidated financial statements for the fiscal year ended December 31, 2022, which are available in the company's Form 20-F filed on March 15, 2023.
The only specific financial data provided relates to auditor fees paid to Kost Forer Gabbay & Kasierer (Ernst & Young Global):
| Fee Category | 2022 | 2021 |
|---|---|---|
| Audit Fees | $365,000 | $291,250 |
| Tax Fees | $186,445 | $187,048 |
| All Other Fees | $0 | $65,000 |
| Total Fees | $551,445 | $543,298 |
Material Changes
- Board Resignation: Mr. Jonathan Hahn, a director since March 2010 and Chairman of the Strategy Committee, resigned effective November 12, 2023, due to other work-related commitments.
- Board Composition: Following Mr. Hahn's resignation, the Board currently consists of nine members. The filing proposes the re-election of seven directors and the election of two external directors to maintain a nine-member board, all of whom are deemed independent under NASDAQ rules.
- Executive Compensation: The Board proposes a 4.17% increase in the CEO's base salary, effective July 1, 2023, raising it from NIS 96,000 to NIS 100,000 per month (approx. $25,990).
Guidance, Outlook, and Risks
The filing does not provide financial guidance, market outlook, or specific risk factors. It notes that the company will present its audited financial statements for 2022 at the Annual General Meeting but will not vote on them. The document highlights that as a foreign private issuer, the company is exempt from certain U.S. proxy rules and follows Israeli law and practice regarding director nominations.
Investor Verification Checklist
- Verify the outcome of the shareholder vote on the CEO's salary increase (Proposal 2) and the election of the new board composition (Proposal 1).
- Review the full audited financial statements for the year ended December 31, 2022, filed on Form 20-F, as this 6-K contains no operational financial data.
- Confirm the appointment of a replacement for Mr. Jonathan Hahn on the Strategy Committee, if applicable, following his resignation.
- Check the company's website or subsequent filings for any updates on the business combination mentioned in the 2021 auditor fee notes.